Follow
Cereno Scientific AB
Spotlight (Sweden)
Cereno Scientific are active within biotechnology. Today, the company is focused on developing pharmaceuticals for the treatment of various cardiovascular diseases. The products are used to treat potential blood clots that may lead to stroke, myocardial infarction, pulmonary embolism, as well as venous thrombosis. The company was founded in 2012 and is based in Mölndal.
Sector:
HEALTH CARE
Instruments & Events
The shares and options available for this company. Including past events like IPOs, direct listings and exercise periods.
Type
Ticker
ISIN
Market
SHARE
CRNO B
SE0008241558
Spotlight
Sweden (SE)
Details of share in Cereno Scientific AB with ticker CRNO B
Status
Active
Order book id
4140
Amount of instruments
71 819 312
Par value
0.1000
Currency
SEK
First trading date
22 Jun 2016
Type
Price
Pre-money valuation
Time
Files
IPO
7.50 SEK
60.4M SEK
26 Apr - 19 May 2016
IPO in Cereno Scientific AB
Type
Price
Pre-money valuation
Time
Files
Rights issue
2.90 SEK
55.63M SEK
23 May - 07 Jun 2019
Share issue in Cereno Scientific AB
Type
Price
Pre-money valuation
Time
Files
Directed issue
1.90 SEK
76.42M SEK
29 Sep - 30 Sep 2020
Share issue in Cereno Scientific AB
Type
Ticker
ISIN
Market
OPTION
CRNO TO1 B
SE0014965687
Spotlight
Sweden (SE)
Details of option in Cereno Scientific AB with ticker CRNO TO1 B
Status
Active
Order book id
77EQ
Amount of instruments
Currency
SEK
Trading period
14 Oct 2020 - 27 Sep 2021
Terms
Each warrant of series TO 1 will give the holder the right to subscribe for one (1) new share of series B during the subscription period from 15 September 2021 until and including 29 September 2021 to a subscription price corresponding to seventy (70) percent of the volume weighted average price of the Company’s share during the period from 30 August 2021 until and including 13 September 2021. The subscription price shall however never be determined to an amount below the quotation value of the Company’s share or to a higher amount than SEK 2.85.
Update (02.10.2020): Record date for distribution of warrants of series TO1 and TO2 to current shareholders is set for October 9, 2020.
Update (09.10.2020): First day of trading in warrants of series TO1 has been set for October 14, 2020.
Type
Price
Pre-money valuation
Time
Files
Exercise
0.10-2.85 SEK
15 Sep - 29 Sep 2021
Option exercise terms for CRNO TO1 B
Type
Ticker
ISIN
Market
OPTION
CRNO TO2 B
SE0014965695
Spotlight
Sweden (SE)
Details of option in Cereno Scientific AB with ticker CRNO TO2 B
Status
Active
Order book id
77ER
Amount of instruments
Currency
SEK
Trading period
14 Oct 2020 - 26 Sep 2022
Terms
Each warrant of series TO 2 will give the holder the right to subscribe for one (1) new share of series B during the subscription period from 14 September 2022 until and including 28 September 2021 to a subscription price corresponding to seventy (70) percent of the volume weighted average price of the Company’s share during the period from 29 August 2022 until and including 12 September 2022. The subscription price shall however never be determined to an amount below the quotation value of the Company’s share or to a higher amount than SEK 3.33.
Update (02.10.2020): Record date for distribution of warrants of series TO1 and TO2 to current shareholders is set for October 9, 2020.
Update (09.10.2020): First day of trading in warrants of series TO2 has been set for October 14, 2020.
Type
Price
Pre-money valuation
Time
Files
Exercise
0.10-3.33 SEK
14 Sep - 28 Sep 2022
Option exercise terms for CRNO TO2 B
People
Sten Sörensen
CEO
Catharina Bäärnhielm
Chairman of the board
Anders Svensson
Board member
Björn Dahlöf
Board member
Jonas Faijerson Säljö
Board member
Klementina Österberg
Board member
Sverker Jern
Board member
Company Details
Sector
HEALTH CARE

Address
C/O Cereno Scientific AB
Zip code
431 83
City/district
Mölndal
Country
Sweden (SE)
Registration number
556890-4071
LEI code
549300VX8KTMYDS6NM84
First trade date
22 Jun 2016
Registration date
12 Apr 2012
Short name
Cereno Scientific

We use cookies to make your experience using IPOhub better. By using our site you agree to our use of cookies. Learn More

Create Your FREE Account to stay Up To Date